close Icon

Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.

Betuela I, Bassat Q, Kiniboro B, Robinson LJ, Rosanas-Urgell A, Stanisic D, Siba PM, Alonso PL, Mueller I

VIEW FULL ARTICLE
  • Journal Antimicrobial agents and chemotherapy

  • Published 17 Jan 2012

  • Volume 56

  • ISSUE 4

  • Pagination 2146-9

  • DOI 10.1128/AAC.05566-11

Abstract

Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.